โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Sponsored by University of Virginia

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Jul 3, 2024

Phase

Clinical Trial

Sponsor

University of Virginia

Enrollment Target

44

Start Date

Jul 2022

๐Ÿ“Š
1 of 44 participants interested
2% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This is a multi-center, open-label phase II study to assess the efficacy of a novel fitness-adapted regimen in previously untreated older patients with classical Hodgkin lymphoma. All participants will receive up to a total of 8 cycles of pembrolizumab (Q6 week dosing). The first cycle of pembrolizumab will be administered in combination with brentuximab vedotin (BV) ("lead-in treatment").

Who Can Participate

Inclusion Criteria

Participants of any sex who are โ‰ฅ60 years of age on day 1, cycle 1.
The participant must be willing and able to provide written informed consent for the trial and participate in all planned study procedures.
Histologically confirmed diagnosis of classical Hodgkin lymphoma
PET-avid, measurable disease (โ‰ฅ1.5cm bi-dimensional measurement)
Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to
PS 2 may be allowed at the discretion of the treating investigator if impairment is considered to be primarily lymphoma-related. Evaluation of ECOG is to be performed within 10 days prior to the date of registration.
Participants who have received involved field radiation will be allowed. However, they will be excluded if any of the following are true: 1. Radiation was dosed โ‰ค6 months from registration. 2. Radiation was delivered to \> 1 lymph node group as defined by the NCCN criteria. 3. The radiation dose was โ‰ฅ30 Gy. 4. The par

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

44 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

University of Virginia

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

New Brunswick

New Jersey

Location available
View New Brunswick location page
NOT_YET_RECRUITING

Philadelphia

Pennsylvania

Location available
View Philadelphia location page
RECRUITING

Charlottesville

Virginia

Location available
View Charlottesville location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Lymphoma Trials by City

Browse all lymphoma clinical trials in these cities โ€” not just this study.

Looking for Hodgkin Lymphoma Treatment in New Brunswick?

Join others in New Jersey exploring innovative treatment options through clinical research

Hodgkin Lymphoma Treatment Options in New Brunswick, New Jersey

If you're searching for Hodgkin Lymphoma treatment in New Brunswick, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in New Brunswick, Philadelphia, Charlottesville and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Hodgkin Lymphoma. All study-related care is provided at no cost to participants.

Local Sites
3 locations in New Jersey
Now Enrolling
Up to 44 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Hodgkin Lymphoma?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Hodgkin Lymphoma

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Hodgkin Lymphoma Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05404945. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.